Cite
HARVARD Citation
Podany, A. et al. (2022). Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine . Clinical infectious diseases. pp. 560-566. [Online].